Metabolic drivers of donor-specific antibodies in transplantation
Official title: Metabolic drivers of donor specific antibody in transplantation
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11426290 · Data updated 2026-11-12
This grant studies why donor antibodies appear after transplantation and how metabolism in the body influences this process, with the goal of preventing antibody-related graft loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 7, 2026 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $608,840 |
| NIH project number | 1R01AI201188-01 |
| Project ID | NIH-11426290 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who have had or are awaiting organ transplantation, especially those with or at risk for donor-specific antibodies or metabolic risk factors like obesity.
✕Less likely to help
Patients without sensitization or obesity-related risks may have limited direct benefit from this research.
What this research studies
In solid organ transplantation, antibodies against donor tissue (DSA) can cause both short-term and long-term graft failure, even when cellular rejection is controlled. This research explores how obesity and metabolic changes affect B cells and antibody production, potentially steering immune responses toward antibody-dominated pathways. By studying both human and animal models, the project aims to identify targets that could reduce DSA formation and improve transplant outcomes. The work may inform new treatments that protect grafts for patients at risk of ABMR.
Why it matters
Potential benefit: If successful, the findings could lead to new strategies to prevent donor-specific antibodies and improve long-term transplant survival.
How similar studies have gone: Prior work suggests that metabolic and B cell pathways influence antibody formation, but translating these insights into therapies remains an ongoing effort.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Gaudette, Brian Thomas — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Gaudette, Brian Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.